{"protocolSection":{"identificationModule":{"nctId":"NCT00652340","orgStudyIdInfo":{"id":"TP2001-201"},"secondaryIdInfos":[{"id":"APRiCOT-L"}],"organization":{"fullName":"Tragara Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer","officialTitle":"APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients","acronym":"TP2001-201"},"statusModule":{"statusVerifiedDate":"2012-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-04"},"primaryCompletionDateStruct":{"date":"2010-06","type":"ACTUAL"},"completionDateStruct":{"date":"2012-03","type":"ACTUAL"},"studyFirstSubmitDate":"2008-03-31","studyFirstSubmitQcDate":"2008-04-02","studyFirstPostDateStruct":{"date":"2008-04-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-03-13","resultsFirstSubmitQcDate":"2012-03-13","resultsFirstPostDateStruct":{"date":"2012-04-09","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-03-13","lastUpdatePostDateStruct":{"date":"2012-04-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Tragara Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients with up-regulated COX-2 expression in tumor will have a clinical benefit compared with erlotinib alone."},"conditionsModule":{"conditions":["Recurrent Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":120,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: apricoxib/erlotinib"]},{"label":"B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: erlotinib/placebo"]}],"interventions":[{"type":"DRUG","name":"apricoxib/erlotinib","description":"apricoxib: 100 mg tablets, 400mg/day\n\nerlotinib: per package insert","armGroupLabels":["A"]},{"type":"DRUG","name":"erlotinib/placebo","description":"erlotinib: per package insert\n\nplacebo: 100 mg tablets, 400 mg/day","armGroupLabels":["B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Time to Disease Progression (TDP)","timeFrame":"Baseline and every other cycle."}],"secondaryOutcomes":[{"measure":"Overall Survival","timeFrame":"Randomization and every cycle"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically determined Stage IV NSCLC including Stage IIIb (pleural effusion)\n* Failed at least one prior platinum-based chemotherapy for Stage IIIb or Stage IV NSCLC. Patients receiving platinum-based chemotherapy only given in an adjuvant setting are not eligible.\n* Measurable disease by RECIST\n* Greater than or equal to 18 years of age\n* ECOG PS of 0 or 1\n\nExclusion Criteria:\n\n* Radiation therapy within 2 weeks; chemotherapy within 3 weeks; non-cytotoxic investigational agents within 4 weeks of initiating study treatment\n* Evidence of NYHA class III or greater cardiac disease\n* History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 12 months\n* Known HIV infection or AIDS\n* Symptomatic CNS metastases\n* Pregnant or nursing women\n* Hypersensitivity or intolerance to erlotinib, sulfonamides, aspirin, or other NSAIDs.\n* History of upper GI bleeding, ulceration, or perforation\n* Prior history of COX-2 inhibitor therapy for the treatment of metastatic NSCLC\n* Previous anti-EGFR kinase therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Tracy Parrott","affiliation":"Tragara Pharmaceuticals, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Tucson","state":"Arizona","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"city":"Bakersfield","state":"California","country":"United States","geoPoint":{"lat":35.37329,"lon":-119.01871}},{"city":"Los Angeles","state":"California","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"city":"Rancho Mirage","state":"California","country":"United States","geoPoint":{"lat":33.73974,"lon":-116.41279}},{"city":"San Diego","state":"California","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"city":"San Dimas","state":"California","country":"United States","geoPoint":{"lat":34.10668,"lon":-117.80673}},{"city":"Stockton","state":"California","country":"United States","geoPoint":{"lat":37.9577,"lon":-121.29078}},{"city":"Norwich","state":"Connecticut","country":"United States","geoPoint":{"lat":41.52426,"lon":-72.07591}},{"city":"Lake North","state":"Florida","country":"United States"},{"city":"Lakeland","state":"Florida","country":"United States","geoPoint":{"lat":28.03947,"lon":-81.9498}},{"city":"Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"city":"Savannah","state":"Georgia","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"city":"Chicago","state":"Illinois","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"city":"Kokomo","state":"Indiana","country":"United States","geoPoint":{"lat":40.48643,"lon":-86.1336}},{"city":"New Albany","state":"Indiana","country":"United States","geoPoint":{"lat":38.28562,"lon":-85.82413}},{"city":"Waterloo","state":"Iowa","country":"United States","geoPoint":{"lat":42.49276,"lon":-92.34296}},{"city":"Louisville","state":"Kentucky","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"city":"New Orleans","state":"Louisiana","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"city":"Ann Arbor","state":"Michigan","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"city":"Jackson","state":"Michigan","country":"United States","geoPoint":{"lat":42.24587,"lon":-84.40135}},{"city":"Lansing","state":"Michigan","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"city":"Livonia","state":"Michigan","country":"United States","geoPoint":{"lat":42.36837,"lon":-83.35271}},{"city":"Saginaw","state":"Michigan","country":"United States","geoPoint":{"lat":43.41947,"lon":-83.95081}},{"city":"Saint Joseph","state":"Michigan","country":"United States","geoPoint":{"lat":42.10976,"lon":-86.48002}},{"city":"Robbinsdale","state":"Minnesota","country":"United States","geoPoint":{"lat":45.03219,"lon":-93.33856}},{"city":"St Louis","state":"Missouri","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"city":"Neptune City","state":"New Jersey","country":"United States","geoPoint":{"lat":40.20011,"lon":-74.02792}},{"city":"Elmhurst","state":"New York","country":"United States","geoPoint":{"lat":40.73649,"lon":-73.87791}},{"city":"Stony Brook","state":"New York","country":"United States","geoPoint":{"lat":40.92565,"lon":-73.14094}},{"city":"Gastonia","state":"North Carolina","country":"United States","geoPoint":{"lat":35.26208,"lon":-81.1873}},{"city":"Wilmington","state":"North Carolina","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"city":"Akron","state":"Ohio","country":"United States","geoPoint":{"lat":41.08144,"lon":-81.51901}},{"city":"Canton","state":"Ohio","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"city":"Columbus","state":"Ohio","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"city":"Jefferson","state":"Ohio","country":"United States","geoPoint":{"lat":41.73867,"lon":-80.76981}},{"city":"Sylvania","state":"Ohio","country":"United States","geoPoint":{"lat":41.71894,"lon":-83.71299}},{"city":"Corvallis","state":"Oregon","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"city":"Portland","state":"Oregon","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"city":"Upland","state":"Pennsylvania","country":"United States","geoPoint":{"lat":39.85261,"lon":-75.38269}},{"city":"Charleston","state":"South Carolina","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"city":"Arlington","state":"Texas","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"city":"Galveston","state":"Texas","country":"United States","geoPoint":{"lat":29.30135,"lon":-94.7977}},{"city":"Newport News","state":"Virginia","country":"United States","geoPoint":{"lat":36.98038,"lon":-76.42975}},{"city":"Richmond","state":"Virginia","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"city":"Tacoma","state":"Washington","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"city":"Huntington","state":"West Virginia","country":"United States","geoPoint":{"lat":38.41925,"lon":-82.44515}},{"city":"Morgantown","state":"West Virginia","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}}]},"referencesModule":{"references":[{"pmid":"24736085","type":"DERIVED","citation":"Gitlitz BJ, Bernstein E, Santos ES, Otterson GA, Milne G, Syto M, Burrows F, Zaknoen S. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Apr;9(4):577-82. doi: 10.1097/JTO.0000000000000082."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Enrolled patients underwent a 5-day open label treatment with apricoxib to determine the maximum suppression of PGEM from a baseline measurment. PGEM was used as a biomarker of COX-2 activity in the tumor. Patients with at least a 50% decrease on day 5 from their baseline measurment were eligible to be randomized.","recruitmentDetails":"The study opened to accural in April 2008. Enrollment closed in May 2010. One hundred seventy six patients were enrolled with 120 patients randomized. Patients were recruited from clinical oncology practices.","groups":[{"id":"FG000","title":"Apricoxib/Erlotinib","description":"Patients randomized to receive apricoxib and erlotinib."},{"id":"FG001","title":"Placebo/Erlotinib","description":"Patients randomized to receive placebo and erlotinib."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"78"},{"groupId":"FG001","numSubjects":"42"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"4 patients remained on study at database lock.","numSubjects":"74"},{"groupId":"FG001","comment":"3 patients remained on study at database lock.","numSubjects":"39"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Had not progressed.","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Apricoxib/Erlotinib","description":"Patients randomized to receive apricoxib and erlotinib."},{"id":"BG001","title":"Placebo/Erlotinib","description":"Patients randomized to receive placebo and erlotinib."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"120"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"69"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"51"}]}]}]},{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.1","spread":"10.78"},{"groupId":"BG001","value":"64.6","spread":"11.16"},{"groupId":"BG002","value":"62.9","spread":"10.94"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"53"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"67"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"120"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Disease Progression (TDP)","populationDescription":"A 1-sided log rank test was used to achieve 80% power at an Î±=0.20 significance level to detect a difference of 0.13 between the proportions of patients who are progression free in AP/E (0.34) and P/E (0.21) after 5 months; an overall sample size of 115 patients (77 in AP/E and 38 in P/E) will be randomized in a 2:1 ratio in this study.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline and every other cycle.","groups":[{"id":"OG000","title":"Apricoxib/Erlotinib","description":"Patients randomized to receive apricoxib and erlotinib."},{"id":"OG001","title":"Placebo/Erlotinib","description":"Patients randomized to receive placebo and erlotinib."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"42"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","lowerLimit":"1.40","upperLimit":"2.80"},{"groupId":"OG001","value":"2.10","lowerLimit":"1.40","upperLimit":"4.00"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization and every cycle","groups":[{"id":"OG000","title":"Apricoxib/Erlotinib","description":"Patients randomized to receive apricoxib and erlotinib."},{"id":"OG001","title":"Placebo/Erlotinib","description":"Patients randomized to receive placebo and erlotinib."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"42"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.90","lowerLimit":"4.10","upperLimit":"8.50"},{"groupId":"OG001","value":"5.60","lowerLimit":"3.80","upperLimit":"9.10"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"First dose of study drug to 30 days after last dose of study drug.","description":"Only drug related serious adverse events are listed.","eventGroups":[{"id":"EG000","title":"Apricoxib/Erlotinib","description":"Patients randomized to receive apricoxib and erlotinib.","seriousNumAffected":13,"seriousNumAtRisk":78,"otherNumAffected":77,"otherNumAtRisk":78},{"id":"EG001","title":"Placebo/Erlotinib","description":"Patients randomized to receive placebo and erlotinib.","seriousNumAffected":4,"seriousNumAtRisk":42,"otherNumAffected":42,"otherNumAtRisk":42}],"seriousEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":42}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Left ventricular dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":42}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Gastric ulcer perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Gastrointestinal hemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":42}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Peritonitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":42}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":42}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]}],"otherEvents":[{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":42,"numAtRisk":78},{"groupId":"EG001","numEvents":23,"numAffected":23,"numAtRisk":42}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":41,"numAffected":41,"numAtRisk":78},{"groupId":"EG001","numEvents":25,"numAffected":25,"numAtRisk":42}]},{"term":"fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":33,"numAtRisk":78},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":42}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":27,"numAtRisk":78},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":42}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":42}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":42}]},{"term":"Anorexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":78},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":42}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":42}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":42}]},{"term":"Mucosal inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":42}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":78},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":42}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":42}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":78},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":42}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":42}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":42}]},{"term":"Pruritis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":78},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":42}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":42}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":78},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":42}]},{"term":"Weight decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":78},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":42}]},{"term":"Edema peripheral","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":78},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":42}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":42}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":42}]},{"term":"Dehydration","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":78},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":42}]},{"term":"Epistaxis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":42}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":42}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":78},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":42}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":42}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":78},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":42}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":42}]},{"term":"Dysgeusia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":42}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":42}]},{"term":"Hypertension","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":78},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":42}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Tracy Parrott","organization":"Tragara Pharmaceuticals","email":"tparrott@tragarapharma.com","phone":"858-350-6919"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C514354","term":"apricoxib"},{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}